AI Consensus Investment Thesis
Argen-X (ARGX) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY€977
+12.1%5-Year
NEUTRAL€1,398
+60.4%Latest flagship insight
Rare Disease Cash Flow Compounding Collides With Long Term Valuation Multiple Compression
High consensus confirms that subcutaneous autoantibody clearance drives substantial commercial operating leverage across chronic autoimmune indications. However, sharp divergence persists regarding whether robust earnings compounding can overcome valuation multiple compression caused by encroaching class competition, statutory payer rebate demands, and elevated long-term sovereign bond yields.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Universal Investor (Polymath), J.P. Morgan (Titan), Superintelligence (Anthropologist), Ray Dalio (Strategist), Warren Buffett (Value Purist), Machiavelli (Insider), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Argen-X at the forecast anchor (2026-09-18): $16,688 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (EUR) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 897.54 | +3.00% | +3.00% | Empasiprubart multifocal motor neuropathy data readout and initial subcutaneous CIDP adoption drive commercial optimism. Strong underlying volume growth is partially counterbalanced by acquisition cash digestion and elevated discount rates capping aggressive valuation multiples. |
| Q1 2027 | 928.60 | +3.46% | +6.56% | Full-year 2026 audited financial reporting confirms expanding operating profitability and accelerating European commercial uptake. Reconciled earnings metrics demonstrate genuine operating leverage, though persistent sovereign bond yields prevent immediate valuation multiple expansion. |
| Q2 2027 | 949.68 | +2.27% | +8.98% | Subcutaneous autoinjector rollout broadens outpatient access and reinforces patient adherence across core neurology indications. Commercial gains face minor friction from tariff pass-through uncertainties and seasonal reimbursement resets, keeping overall appreciation measured and orderly. |
| Q3 2027 | 976.74 | +2.85% | +12.09% | International commercial expansion across Europe and Japan broadens recurring revenues, offsetting seasonal summer prescription slowdowns. Rising interest rate headwinds and cautious valuation discounting temper market enthusiasm, resulting in modest fundamental earnings-driven price progress. |
| Q4 2027 | 1,011.71 | +3.58% | +16.10% | Late-stage clinical trial updates in rheumatology indications yield supportive efficacy markers, validating platform adjacency. Robust quarterly free cash flow generation reinforces balance-sheet resilience, attracting institutional capital into year-end portfolio positioning. |
| Q1 2028 | 1,033.16 | +2.12% | +18.56% | Fiscal 2027 financial disclosures reveal operating margins consolidating above thirty percent. Sustained patient volume gains across established territories offset early payer rebate renegotiations, supporting steady multiple consolidation across major European exchanges. |
| Q2 2028 | 1,064.67 | +3.05% | +22.18% | Regulatory approvals for adjacent neuromuscular indications broaden addressable commercial volume. Strong clinical switching barriers protect established core revenue streams, though advancing competitive pipeline disclosures from rival pharmaceutical developers introduce headline caution. |
| Q3 2028 | 1,064.24 | -0.04% | +22.13% | Head-to-head competitive clinical disclosures and aggressive pharmacy benefit manager contracting talks generate tactical sentiment friction. Established physician loyalty cushions market share, limiting performance to narrow consolidation as investors weigh pricing sustainability. |
| Q4 2028 | 1,101.07 | +3.46% | +26.36% | Relief following competitive data presentations and solid commercial execution in peripheral neuropathies restores buying momentum. Accelerating operating cash conversion and disciplined research expense management drive healthy quarterly valuation support into year-end. |
| Q1 2029 | 1,128.81 | +2.52% | +29.54% | Full-year 2028 results confirm steady top-line compounding, while management demonstrates rigorous operational expense containment. Steady cash generation reinforces self-funding credentials, though valuation multiples face gradual downward pressure as organic percentage growth normalizes. |
| Q2 2029 | 1,163.24 | +3.05% | +33.49% | Commercial launches across newly approved rheumatological indications unlock fresh volume streams, offsetting modest competitive pricing concessions. Subcutaneous convenience preserves high prescriber adherence, translating expanded patient onboarding into durable operating earnings growth. |
| Q3 2029 | 1,181.74 | +1.59% | +35.61% | Routine annual payer formulary renegotiations and international pricing reference adjustments create mild gross-to-net drag. Resilient baseline prescription refills and expanding Asian market contributions cushion bottom-line earnings, enabling modest quarterly price advancement. |
| Q4 2029 | 1,220.97 | +3.32% | +40.12% | Late-stage pipeline progression and maturing complement platform readouts reassure markets regarding long-term revenue durability. Healthier macroeconomic liquidity conditions provide modest multiple support, allowing accelerating net earnings to drive a solid quarterly advance. |
| Q1 2030 | 1,244.54 | +1.93% | +42.82% | Annual 2029 financial disclosures highlight strong free cash flow conversion exceeding three billion dollars. Mature growth rates naturally moderate, prompting the valuation multiple to compress toward specialty pharmaceutical norms despite resilient cash generation. |
| Q2 2030 | 1,253.99 | +0.76% | +43.91% | Next-generation pipeline candidates advance toward registrational milestones, partially dispelling long-term patent expiration anxieties. Competitor market entries in mature indications induce minor multiple compression, offset by steady cash accumulation on the balance sheet. |
| Q3 2030 | 1,284.84 | +2.46% | +47.45% | Commercial execution across diversified indications maintains consistent cash flow generation, while high switching costs protect core neurology volume. Steady operational performance provides a reliable valuation floor, generating measured quarterly share price appreciation. |
| Q4 2030 | 1,317.86 | +2.57% | +51.24% | Progress toward multi-indication corporate patient targets confirms operational maturity and robust recurring earnings. Sustained free cash flow accumulation sparks institutional speculation regarding potential shareholder capital returns, supporting positive equity performance into year-end. |
| Q1 2031 | 1,345.93 | +2.13% | +54.46% | Full-year 2030 reporting illustrates elite biopharmaceutical operating margins near thirty-five percent. Exceptional cash conversion and pristine liquidity preserve defensive strength, though terminal multiple moderation limits quarterly price gains to underlying operational progress. |
| Q2 2031 | 1,370.29 | +1.81% | +57.25% | Next-generation FcRn antibody development de-risks future franchise lifecycle transitions, mitigating biosimilar surveillance concerns. High recurring therapy demand and international market contributions sustain predictable cash flows, driving steady, low-volatility quarterly price appreciation. |
| Q3 2031 | 1,397.84 | +2.01% | +60.41% | The five-year horizon concludes with the business firmly established as a profitable, cash-generative global immunology leader. Mature earnings compounding and defensive patent moats justify a solid valuation baseline, delivering dependable terminal equity compounding. |
The investment thesis centers on a commercial biopharmaceutical powerhouse transitioning into self-funding cash generation. High switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy anchor durable prescription volumes at gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near 89%. Because commercial sales infrastructure is largely fixed, incremental label expansions into adjacent rheumatological conditions generate powerful operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, driving operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward 35%. However, the equity is not cheap; reconciling half-year filings reveals true trailing multiples near 40x rather than screened 27x figures. Long-term returns depend entirely on operational earnings compounding outpacing inevitable valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry contraction.
Key insights
- High patient switching barriers and subcutaneous autoinjector convenience protect core neurology revenues from immediate displacement by later-entering competitor molecules across outpatient clinics.
- Fixed commercial sales infrastructure absorbs adjacent autoimmune indications with minimal marginal expense, enabling free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry to compound faster than top-line revenue.
- Mandatory pharmacy benefit manager rebates and advancing rival FcRn inhibitors will compress terminal pricing, making volume expansion the primary earnings driver.
The company has evolved from a loss-making drug developer into a profitable commercial enterprise. Its flagship autoimmune treatment acts like a specialized medical tollbooth: once patients stabilize, doctors rarely switch them to alternative drugs. While the stock already reflects strong near-term growth, the business continues to generate substantial cash that funds new clinical programs without borrowing, even as competition and insurance discounts gradually trim future profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry.
Key insights
- Doctors and stabilized patients rarely abandon effective chronic treatments, creating sticky and dependable prescription revenues.
- Selling multiple treatments through an existing specialist salesforce allows profits to grow much faster than company expenses.
- Incoming rival medications and insurer price negotiations will slow price increases, requiring steady patient volume growth instead.
Deep Dive
Market consensus frames the company as European biotechnology's premier growth compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry, extrapolating 60% historical sales expansion and treating multi-indication approval across systemic autoimmunity as practically assured. Sell-side commentary heavily anchors on an unadjusted screening multiple near 27 times earnings, largely dismissing pipeline execution setbacks, looming pricing pressure from rival FcRn developers, and statutory rebate extractions by health insurance payers.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus frames the company as European biotechnology's premier growth compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry, extrapolating 60% historical sales expansion and treating multi-indication approval across systemic autoimmunity as practically assured. Sell-side commentary heavily anchors on an unadjusted screening multiple near 27 times earnings, largely dismissing pipeline execution setbacks, looming pricing pressure from rival FcRn developers, and statutory rebate extractions by health insurance payers.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd moderately underestimates value through an analytical misread of operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, yet simultaneously overestimates near-term valuation cheapness due to screening data errors. While casual screens suggest a modest 27x trailing multiple on 7.6 billion dollars of revenue, reconstructed financial filings show true product revenue near 5.2 billion dollars, revealing a steeper 38x multiple. Crucially, the market fails to appreciate how fixed commercial infrastructure allows incremental indication revenues to convert into operating cash flows far faster than consensus anticipates.
Repricing Catalyst
What could make the market recognize and close that gap? Pivotal registrational readouts for empasiprubart in multifocal motor neuropathy alongside commercial sales disclosures demonstrating operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry exceeding 30% serve as the decisive convergence catalyst cluster. Demonstrating clinical efficacy in non-FcRn biology breaks single-molecule dependency narratives, while widening cash generation will force sell-side analysts to lift multi-year operating cash-flow estimates over the twelve-to-twenty-four-month monitoring window.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Momentum
Reports agree on strong commercial momentum but diverge sharply on valuation risk. While optimistic views anticipate continued multiple stability, contrarian analyses warn that peak cyclical sentiment and oncoming competitive launches leave the equity vulnerable to multiple contraction.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic setup is a mixed backdrop leaning slightly adverse for valuation multiples. A restrictive monetary policy environment with 5% sovereign bond yields exerts mechanical downward pressure on long-duration equity multiples. Conversely, inelastic clinical demand for life-altering autoimmune biologics and a fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry holding over three billion dollars in net cash provide complete operational insulation from credit tightening.
Advisor Disagreement
What do our AI Advisors disagree about most? The core debate centers on starting valuation and competitive duration. Optimistic views model uninterrupted multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry above 30x forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry, assuming subcutaneous convenience and prescriber stickiness permanently insulate the franchise from competitor entry. Conversely, skeptical assessments argue that true trailing earnings multiples sit near 40x rather than screened 27x figures, warning that incoming FcRn rivals and statutory payer rebates will compress operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and multiples toward mature specialty pharmaceutical norms. Observable quarterly net realized pricing trends and comparative Phase 3 data from rival molecules throughout 2027 will resolve this valuation divide.
Base-Case Forces
Event Risk ScoreModerate47/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multi-indication autoimmune franchise label expansion | Innovation And Product | +34% | +52% | Systematic clinical label expansion of efgartigimod beyond generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy into rheumatology targets over 50,000 global patients. Because manufacturing batches and clinical foundations are already established, each incremental approval delivers high-margin volume that widens operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, expanding long-term earning power across the five-year horizon. |
| Commercial operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry cash conversion | Operational Efficiency | +24% | +40% | Elite gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry near 89% combine with an established global sales organization to drive rapid operational leverage. Having crossed structural profitability, selling expenses scale sub-linearly with new indication rollouts. This dynamic widens operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry toward 35%, converting top-line commercial growth into accelerating free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry that compounds per-share intrinsic business value. |
| Subcutaneous convenience locks prescriber switching | Competitive Positioning | +20% | +28% | Widespread adoption of subcutaneous Vyvgart Hytrulo and prefilled autoinjectors displaces burdensome hospital infusions, achieving patient adherence above 85%. Once chronic neurological patients achieve clinical disease stability at home, neurologists face steep behavioural switching barriers against altering regimens. This entrenched prescriber loyalty protects core market share and insulates commercial volume from early competitor incursions. |
| Debt-free fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry self-funding | Capital Allocation | +14% | +18% | Operating with virtually zero debt and substantial liquid reserves shields the business from credit contractions and elevated benchmark interest rates. Strong internal operating cash flows fully self-fund ten parallel registrational clinical trials and selective bolt-on acquisitionsbolt on acquisitionsPurchases of smaller businesses intended to add products, capabilities, customers, or geographic reach to an existing operation.View full glossary entry without equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry, preserving per-share capital compounding while competitors face capital-market financing constraints. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Rival FcRn class competitive encroachment | Competitive Positioning | -16% | -20% | Emerging neonatal Fc receptor antagonists from well-funded multinational pharmaceutical competitors contest core neurology indications. Although first-mover physician loyalty provides a strong defense, incoming alternatives force elevated promotional spending and aggressive hospital formulary rebating. This competitive crowding caps terminal net realized pricing per patient, tempering prospective operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion across outer forecast years. |
| Macroeconomic duration multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry drag | Macroeconomic And Macrofinancial | -15% | -4.0% | A higher-for-longer monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry featuring elevated sovereign bond yields imposes mechanical downward pressure on high-multiple growth equities. Trading at roughly 38-40 times normalized earnings, the equity faces inevitable multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry as discount rates penalize outer-year terminal cash flows. This duration tax absorbs a meaningful portion of underlying operational earnings growth over the horizon. |
| Payer utilization restrictions and statutory rebates | Regulatory | -13% | -16% | Intensifying healthcare budget scrutiny across the United States and Europe generates persistent downward pressure on specialty biologic reimbursements. Commercial insurers increasingly enforce step therapy, prior authorizations, and higher gross-to-net statutory rebates before approving chronic therapy. This administrative friction lengthens patient onboarding cycles, forcing unit volume to shoulder the entire top-line expansion burden. |
| Heavy registrational clinical research expenditure | Capital Allocation | -10% | -14% | Simultaneously advancing ten clinical-stage registrational programs across multiple rare diseases consumes over 1.5 billion dollars in annual research expenditures. High patient recruitment costs in rare cohorts, trial complexity, and ongoing post-acquisition integration outlays absorb substantial gross profit. This persistent reinvestment burden constrains near-term free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry expansion, deferring peak operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry realization. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Pivotal registrational clinical trial endpoint failure | 30% | -28% | A high-profile Phase 3 trial failure in an advanced pipeline indication, such as autoimmune myositis or multifocal motor neuropathy, would severely impair market confidence. Triggered by an inability to achieve statistical significance versus placebo, this setback would invalidate multi-franchise expansion assumptions, prompting immediate earnings write-downs, pipeline restructuring, and sharp equity multiple derating. |
| Severe postmarketing chronic infection safety signal | 16% | -38% | Commercial real-world pharmacovigilance identifying severe opportunistic infection clusters or paradoxical immune toxicities from prolonged systemic IgG clearance could trigger FDA black-box warnings or restrictive patient monitoring requirements. This regulatory intervention would paralyze new patient onboarding, accelerate prescriber hesitation, and trigger sharp downgrades to peak penetration across chronic neurological and rheumatological indications. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Empasiprubart pivotal breakthrough in motor neuropathy | 38% | +28% | Topline Phase 3 registrational success for empasiprubart in multifocal motor neuropathy would validate a second proprietary biologic platform targeting C2 complement inhibition. Triggered by statistically superior functional stabilization data, this breakthrough would establish an independent multi-billion-dollar rare disease franchise, dispelling single-molecule concentration concerns and prompting institutional analysts to aggressively raise long-term terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples. |
| Blockbuster registrational victory in Sjogrens syndrome | 32% | +32% | Positive pivotal Phase 3 registrational readouts for efgartigimod in primary Sjögren's syndrome would unlock a prevalent rheumatological population exceeding 300,000 addressable patients currently lacking approved targeted biologic therapies. This clinical triumph would expand peak addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry potential by over four billion dollars annually, triggering substantial consensus earnings upgrades and accelerating enterprise free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry compounding. |
Company Financial Analysis
Argen-X Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The company has completed a historic turnaround, transitioning from heavy development-stage cash losses into substantial commercial profitability. Product revenue surged 84.7% in fiscal 2025 to 4.15 billion dollars, driven by rapid patient adoption of Vyvgart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Reconstructed financial filings indicate true trailing product sales near 5.2 billion dollars through mid-2026. This explosive trajectory reflects genuine operating leverage rather than transient accounting windfalls. As recurring prescription volumes expand across specialized neurology clinics, operating income and cash flows have turned decisively positive. Patient demand for life-altering therapies remains highly predictable, providing a dependable foundation for long-term cash generation.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 4.2B | USD 1.3B | USD 876M |
| 2024 | USD 2.2B | USD 833M | USD -84.5M |
| 2023 | USD 1.2B | USD -295.1M | USD -464.1M |
| 2022 | USD 410.7M | USD -709.6M | USD -966.6M |
| 2021 | USD 528.3M | USD -408.3M | USD -728.2M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 33.8x | TTM | USD-normalized | EUR / USD |
| 2024 | 55.1x | TTM | USD-normalized | EUR / USD |
| 2023 | -- | TTM | Loss-making | EUR / USD |
| 2022 | -- | Annual | Loss-making | EUR / USD |
| 2021 | -- | Annual | Loss-making | EUR / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability trends highlight the remarkable economic power of proprietary biologic therapies. Gross margins remained stellar at 89.1% in fiscal 2025, reflecting exceptional pricing power and low incremental manufacturing costs per dose. Operating margins swung dramatically from negative territory in 2024 to 24.8% in 2025, climbing above 30% in mid-2026. This structural margin explosion stems from classic operating leverage. Because marketing and medical affairs teams cover concentrated specialist networks, sales overhead grows much slower than overall revenue. As new indications utilize the same sales infrastructure, incremental revenue drops straight to the bottom line, establishing a durable high-margin profile.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 1B | 24.8% | 32.4% |
| 2024 | USD -21.7M | -1.0% | 37.1% |
| 2023 | USD -425M | -34.7% | -24.1% |
| 2022 | USD -720.3M | -175.4% | -172.8% |
| 2021 | USD -348.7M | -66.0% | -77.3% |
Balance sheet and leverage
AI Review
The balance sheet is designed as an impenetrable financial fortress, providing complete operational autonomy during volatile economic environments. Total assets stood at 8.68 billion dollars against 7.32 billion dollars in shareholder equity at year-end 2025. With a debt-to-equity ratio of just 0.01 and a current ratio exceeding 5.2, the company carries virtually no financial debt. This pristine solvency profile fully insulates operations from high central bank interest rates and credit market contractions. Even after committing 2.2 billion dollars in cash to acquire Forte Biosciences post-period, remaining liquidity comfortably funds late-stage clinical trials internally, eliminating the need for dilutive equity offerings or costly debt issuance.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 47.2M | USD 4.4B | USD 3.4B net cash | 5.23x |
| 2024 | USD 37.7M | USD 3.4B | USD 1.5B net cash | 7.29x |
| 2023 | USD 20M | USD 3.2B | USD 2B net cash | 9.75x |
| 2022 | USD 12.4M | USD 2.2B | USD 788.3M net cash | 9.18x |
| 2021 | USD 11.5M | USD 2.3B | USD 1.3B net cash | 8.44x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains an exceptionally capital-light operating structure, spending almost nothing on physical property, factories, or heavy machinery. In fiscal 2025, physical capital expenditure accounted for a negligible 0.15% of total revenue. Instead of building expensive manufacturing facilities, the company outsources biologic production to specialized contract development partners like Fujifilm. This disciplined strategy frees up operational cash to be reinvested straight into intellectual property and clinical trials. Research spending reached 1.42 billion dollars in 2025 to advance ten parallel registrational programs. While this clinical intensity absorbs substantial near-term cash, it maximizes return on invested capital by avoiding factory depreciation and fixed plant obsolescence.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 6.4M | USD 1.4B |
| 2024 | USD 1.7M | USD 949.3M |
| 2023 | USD 43.8M | USD 859.5M |
| 2022 | USD 103.8M | USD 663.4M |
| 2021 | USD 121.4M | USD 580.5M |
Quarterly Forecast Scenarios
Argen-X Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in EUR; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (EUR) | Base case (EUR) | Bull case (EUR) | S&P 500 benchmark (USD) | FX (EUR/USD) |
|---|---|---|---|---|---|
| €836.54 | €906.88 | €949.83 | $750.26 | 1.1360 | |
| €870.01 | €941.34 | €1,016 | $736.44 | 1.1255 | |
| €896.11 | €972.44 | €1,077 | $743.40 | 1.1272 | |
| €914.49 | €1,000 | €1,131 | $755.15 | 1.1312 | |
| €877.91 | €1,043 | €1,222 | $776.22 | 1.1401 | |
| €860.36 | €1,067 | €1,295 | $787.13 | 1.1452 | |
| €886.17 | €1,100 | €1,347 | $802.83 | 1.1510 | |
| €841.86 | €1,119 | €1,441 | $812.05 | 1.1584 | |
| €816.60 | €1,162 | €1,556 | $839.18 | 1.1617 | |
| €800.27 | €1,196 | €1,650 | $850.50 | 1.1694 | |
| €816.28 | €1,234 | €1,732 | $872.39 | 1.1719 | |
| €783.63 | €1,258 | €1,801 | $885.51 | 1.1763 | |
| €767.95 | €1,306 | €1,928 | $909.56 | 1.1781 | |
| €775.63 | €1,334 | €2,043 | $916.13 | 1.1832 | |
| €752.36 | €1,361 | €2,145 | $936.51 | 1.1867 | |
| €759.89 | €1,395 | €2,231 | $947.34 | 1.1894 | |
| €744.69 | €1,438 | €2,365 | $969.59 | 1.1887 | |
| €759.58 | €1,473 | €2,483 | $979.99 | 1.1913 | |
| €751.99 | €1,504 | €2,583 | $999.60 | 1.1971 | |
| €759.51 | €1,539 | €2,686 | $1,012 | 1.1964 |
Behind the synthesis
How each opinion shapes the consensus
Across the submitted evaluations, an independently supported pattern confirms that commercial execution in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy generates substantial operating leverage over an established sales chassis. However, several reports uncritically propagate a flawed screening dataset claiming 7.6 billion dollars in trailing revenue and a 26.7x multiple, which incorrectly aggregates half-year cumulative totals. Primary SEC and corporate filings reveal true trailing product revenues near 5.2 billion dollars, placing the actual earnings multiple closer to 38x. The strongest contrarian case emphasizes that second-generation competitors and mandatory payer rebates will erode realized pricing just as higher benchmark yields depress growth multiples. Evaluations that forensically corrected the financial baseline and accounted for post-balance-sheet cash deployment, such as the Forte Biosciences acquisition, receive the highest weights. Overly euphoric trajectories assuming perpetual multiple expansion amid encroaching class competition are heavily downweighted to ensure realistic risk-adjusted synthesis.
Universal Investor AI
The Polymath
Opus 5This rigorous evaluation stands out by forensically reconciling financial filings, debunking inflated screening database revenues, and identifying true valuation multiples near 40x. Its causal modeling soundly integrates Section 232 tariff considerations, duration drag, and competitive head-to-head friction, providing superior evidence-based discipline that justifies high relative weighting.
Universal Investor AI
The Polymath
GPT-6 AstraThis perspective provides exceptional analytical rigor by directly adjusting for the $2.2 billion Forte Biosciences acquisition and reconciling actual TTM product revenues to roughly $5.2 billion. Its disciplined recognition that multiple contraction will offset part of operational growth delivers superior causal consistency, warranting top weighting.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis report accurately recognizes that price-to-sales multiples face inevitable contraction from 8.5x toward 5.5x as the core franchise matures. Its realistic recognition of payer pushback and commercial step-therapy tempers top-line optimism, though it still relies on unadjusted trailing revenue datasets, earning a moderate weight.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThis contrarian perspective provides a vital counterweight by rigorously modeling competitive erosion from next-generation FcRn entrants and aggressive pharmacy benefit manager rebate extraction. Even though its terminal volume stagnation is overly severe, its multiple contraction logic provides essential risk discipline, earning meaningful weight.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashThe evaluation correctly identifies all-weather operational insulation and non-discretionary autoimmune treatment demand amid restrictive monetary policy. Its analysis balances top-line growth with multiple compression risks. Nevertheless, reliance on aggregated database revenue metrics without reconciling half-year filing figures slightly impairs its causal foundation, justifying a controlled weight.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThis report delivers detailed operational analysis of neuromuscular prescribers, supply-chain commitments, and outsourced manufacturing dynamics. While it relies on unadjusted screening datasets, its careful treatment of partner royalties, manufacturing obligations, and commercial reimbursement hurdles provides grounded qualitative evidence, warranting a solid weight.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis assessment grounds switching costs in patient convenience and first-principles biological mechanics. However, it incorporates unadjusted trailing revenue data and understates the friction of payer step-therapy and statutory price concessions, justifying a moderate, well-calibrated weighting.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis perspective articulates valid switching costs in chronic neuromuscular care and capital-light biologic manufacturing. However, it relies on unadjusted screened sales metrics, uncritically accepts headline cash figures without deducting post-period commitments, and overstates terminal multiple resilience in a high-rate regime, warranting a modest weighting.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThis analysis provides useful insights into orphan drug exclusivity perimeters and switching costs for subcutaneously treated patients. However, it assumes an aggressive 26x terminal forward multiple and overstates mid-term operating cash flow conversion while repeating unadjusted screening database numbers, warranting a tempered allocation.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThe report offers sound qualitative commentary regarding sub-linear commercial cost scaling across adjacent neurological and rheumatological indications. However, it relies heavily on unverified database metrics, neglects post-period cash outlays for pipeline acquisitions, and adopts an optimistic stance toward multiple stability, justifying a reduced weight.
Universal Investor AI
The Polymath
Gemini 3.8 FlashWhile effectively framing commercial operating leverage and prescriber stickiness, this report accepts screened financial metrics without reconciling underlying half-year SEC filings. Its expectation of forward multiple expansion to 32x normalized earnings conflicts with tighter monetary conditions and competitive class entry, necessitating a lower weight.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThe analysis provides credible mechanics on autoinjector patient persistence and second-generation pipeline development. However, it models aggressive earnings compounding while repeating distorted trailing twelve-month revenue data and projecting multiple expansion that understates prospective pricing resistance, justifying a conservative weight.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAlthough capturing the commercial power of 89% gross margins, this report exhibits extreme optimism by projecting 104% returns. It relies on distorted screening figures and assumes sustained high multiples despite emerging class rivals and tightening reimbursement, requiring a heavy discount for uncritical assumptions.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashThis report presents an overly promotional narrative projecting a tripling of equity value and $16.5 billion in revenue. It ignores multiple compression arithmetic, downplays competitor launches, and relies on distorted screened financials, warranting the lowest assigned weight due to poor analytical realism.
Research Provenance
References & Context
This Argen-X consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 73 deduplicated sources retained for this batch.
- 01ARGENX SE - Form CORRESP - FY2025sec.gov
- 02Argenx stock holds near recent highs as Jefferies sticks to Buy ratingad-hoc-news.de
- 03argenx | argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositisargenx.com
- 04argenx | argenx Completes Acquisition of Forte Biosciences, Inc.argenx.com
- 05argenx | argenx Highlights 2026 Strategic Prioritiesargenx.com
- 06argenx | argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Updateargenx.com
- 07argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Updateargenx.com
- 08argenx | argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Updateargenx.com
- 09argenx | argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipelineargenx.com
- 10Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
- 11U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
- 12Check out argenx SE's stock price (ARGX) in real timecnbc.com
- 13ARGX Stock Quote Price and Forecast | CNNcnn.com
- 14FcRn Inhibitor Drug Market Size, Trends, Growth Report 2033databridgemarketresearch.com
- 15A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
And 58 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
4 fieldscapitalExpenditures · freeCashFlow · salePurchaseOfStock · totalCashFromOperatingActivities
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: EUR, USD (quote EUR; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.